Current treatment options for SMA have revolutionized care for thousands of patients, effectively extending lifespan, preventing the loss of motor function in pre-symptomatic patients, and delaying progression in symptomatic patients by increasing full-length SMN protein levels(13, 24, 86, 87, 91, 100). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.